Business Context and Reporting Period
Company: Techne Corporation (BIO-TECHNE Corp)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: September 30, 1996
Operations: The Company operates through two primary subsidiaries: Research & Diagnostic Systems, Inc. (R&D Systems) in Minneapolis and R&D Systems Europe Ltd. in Abingdon, England. R&D Systems comprises Biotechnology (cytokines, antibodies, assay kits) and Hematology (controls and calibrators) divisions. R&D Europe distributes these products in Europe and manufactures its own biotechnology lines.
Key Financial Metrics
| Metric | Q1 FY1997 (Ended 9/30/96) | Q1 FY1996 (Ended 9/30/95) |
|---|---|---|
| Net Sales | $14,026,978 | $12,794,298 |
| Gross Margin | $9,248,848 (65.9%) | $8,130,401 (63.5%) |
| Net Earnings | $2,175,269 | $1,785,282 |
| Earnings Per Share (Diluted) | $0.22 | $0.18 |
| Cash & Cash Equivalents | $5,615,788 | $5,984,732 |
| Short-term Investments | $12,307,451 | N/A (Not reported in prior period balance sheet) |
| Total Current Assets | $31,781,632 | N/A |
| Total Current Liabilities | $4,969,552 | N/A |
| Net Cash from Operating Activities | $2,592,426 | $2,089,542 |
| Net Cash Used in Investing Activities | ($2,884,141) | ($1,221,317) |
| Net Cash Used in Financing Activities | ($1,528,505) | ($215,125) |
Liquidity: Total cash and short-term investments stood at $17,923,239 as of September 30, 1996. The Company maintains an unsecured line of credit of $750,000 with no borrowings during the quarter.
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 10% ($1.23 million) year-over-year. This was driven by a 9% increase in R&D Systems sales and a 12% increase in R&D Europe sales.
- Product Mix Shift: Biotechnology products now account for 83% of consolidated sales (up from 77%), contributing to a gross margin expansion from 63.5% to 65.9%. Cytokine sales rose $755,146 and Quantikine kit sales rose $429,083.
- Hematology Decline: Hematology product sales decreased by $435,933, primarily due to the loss of an OEM customer at the end of the prior fiscal year.
- Expense Increases:
- Selling, General & Administrative (SG&A) expenses rose 7% ($216,564), attributed to added sales/marketing staff and increased advertising.
- Research & Development (R&D) expenses rose 16% ($391,176), driven by new product development and additional laboratory space.
- Tax Rate: The effective tax rate decreased to approximately 30% from 32%, due to the reinstatement of the R&D tax credit and benefits from the foreign sales corporation.
Guidance, Outlook, and Risks
Capital Expenditures: The Company plans to spend approximately $4.2 million on capital additions for the remainder of fiscal 1997, primarily for facility expansion and remodeling, funded by operating cash flows.
Share Repurchases: The Company continues a program to purchase and retire up to $5,000,000 of common stock. As of November 1, 1996, 140,000 shares had been repurchased for $2,850,401. No dividends are planned.
Risks and Contingencies:
- Market acceptance of new biotechnology and hematology products.
- Price competition from a growing number of cytokine producers.
- Retention of hematology OEM and proficiency survey business.
- Success of marketing expansion efforts in Europe.
Investor Verification Checklist
- Sustainability of Biotech Growth: Verify if the 10% revenue growth and margin expansion are sustainable given the shift away from the declining Hematology division.
- OEM Customer Impact: Assess the long-term impact of the lost OEM customer on the Hematology division's future revenue trajectory.
- Capital Allocation: Review the $4.2 million planned capital expenditure for facility expansion to ensure it aligns with projected revenue growth.
- Share Repurchase Progress: Monitor the pace of the $5 million share repurchase program and its impact on earnings per share.
- European Expansion: Evaluate the performance of the new German sales subsidiary and its contribution to R&D Europe's 12% sales increase.